SCHEMBL6134626

SCHEMBL6134626

COCCCCCOc1ccc(-c2cnc(N)s2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.72
NPC1 O15118 4/20 0.72
SMN1; SMN2 Q16637 4/20 0.72
MAPT P10636 2/20 0.72
ALDH1A1 P00352 2/20 0.72
LMNA P02545 1/20 0.46
CSNK2A1 P68400 2/20 0.46
KDM4E B2RXH2 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HDAC1 Q13547 3/20 0.41
HDAC6 Q9UBN7 3/20 0.41
CYP2D6 P10635 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
POLB P06746 1/20 0.40
QPCT Q16769 1/20 0.40
QPCTL Q9NXS2 1/20 0.40
CHEK1 O14757 1/20 0.39
AOC3 Q16853 2/20 0.39
CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL558170 0.80 MAPT (0.67) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL3107207 0.77 RAB9A (0.76) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL20312081 0.76 CYP3A4 (0.52) L3MBTL1HDAC1HDAC6CYP2D6CYP1A2
SCHEMBL22684972 0.75 SMN1; SMN2 (0.60) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL6134623 0.75 HDAC3 (0.43) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL25386075 0.74 CYP2D6 (0.47) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL17963279 0.72 TDP1 (0.55) RAB9ANPC1MAPTALDH1A1CYP2D6
SCHEMBL15581289 0.71 MAPT (0.50) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL17963081 0.70 TDP1 (0.57) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL12091997 0.70 CSNK2A1 (0.62) RAB9ANPC1SMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261177-A1 Compound ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed
EP-1366066-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-12-03 EP disclosed
WO-2002072621-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261177-A1 Compound MANBA, MAN2B1, MAN2A1 RAB9A 3326/4885NPC1 1070/4885SMN1; SMN2 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.